NeoGenomics, Inc. (NASDAQ:NEO)
About the company
NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Gross Margin (in %)
Operating Margin (in %)
Net Margin (in %)
Dividend Yield (in %)
|Name||Ticker||Market capitalization (in USD Million)||Revenues (in USD Million)||Price/Book||Price/Earning||Net margin (in %)|
|Guardant Health, Inc.||GH||7770.15||245.00||10.52||-100.66||-31.53|
|LHC Group, Inc.||LHCG||5555.20||2091.00||3.96||56.53||4.73|
|1Life Healthcare, Inc.||ONEM||4827.06||292.00||10.38||-60.81||-27.31|
|The Ensign Group, Inc.||ENSG||2376.08||2155.00||3.37||19.20||5.76|
|Acadia Healthcare Co., Inc.||ACHC||2250.16||3130.00||0.92||19.98||3.61|
|Addus HomeCare Corp.||ADUS||1264.90||598.00||2.99||61.46||3.33|
|U.S. Physical Therapy, Inc.||USPH||1056.38||478.00||4.33||35.96||6.03|
|Castle Biosciences, Inc.||CSTL||675.07||61.00||8.75||661.83||9.75|
|The Pennant Group, Inc.||PNTG||640.64||352.00||8.38||152.53||1.19|
|Option Care Health, Inc.||OPCH||627.36||2539.00||2.65||-6.41||-3.63|
|Tivity Health, Inc.||TVTY||540.00||1255.00||70.31||-1.09||-38.98|
|Fulgent Genetics, Inc.||FLGT||324.20||35.00||4.32||-1621.00||-1.31|
|American Renal Associates Holdings, Inc.||ARA||205.12||824.00||-2.54||-11.45||-2.19|
|CRH Medical Corp.||CRHM||163.52||117.00||2.15||112.00||1.52|
|Guardion Health Sciences, Inc.||GHSI||35.70||1.00||2.62||-1.56||-824.43|
|Cardiff Oncology, Inc.||CRDF||30.17||0.00||12.31||-1.97||-883.77|
|OncoSec Medical, Inc.||ONCS||25.61||None||2.10||-0.68||None|
|Capital Senior Living Corp.||CSU||20.16||439.00||-0.64||-0.29||-16.00|
|American Shared Hospital Services||AMS||12.66||20.00||0.46||52.75||1.28|
|IMAC Holdings, Inc.||IMAC||10.98||16.00||1.26||-1.63||-42.30|
Latest insider transactions
|Date||Role||Name||Transaction||Quantity||Quantity Owned After|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use ...
NeoGenomics, Inc.: NeoGenomics Launches Comprehensive Suite of Solid Tumor Liquid Biopsy Tests for Cancer Patients
FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of three liquid biopsy tests for ...
NeoGenomics (NEO +5.3%) launches three liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases. These new tests provide a ...
Research Triangle Park, NC, USA and Cambridge, UK June 29, 2020 – Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO), its strategic commercialization partner in ...
With this in mind, let’s take a look at the recent hedge fund activity surrounding Riverview Bancorp, Inc. (NASDAQ:RVSB) and determine whether hedge funds had an edge regarding this stock. Hedge funds ...
FT. MYERS, FL / ACCESSWIRE / June 29, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of three liquid biopsy tests ...